

Corrected Press Release

Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to former Acieux shareholders following the US FDA's approval of the new drug application in the US for ZERVIAE (cetirizine ophthalmic solution) 0.24%.

8 June 2017
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, has announced a capital increase of a nominal amount of €597,897 by means of the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares following the approval by the US FDA (Food and Drug Administration) of the new drug application in the US for ZERVIAE (cetirizine ophthalmic solution) 0.24% (see the Company's press release of 31 May 2017), in order to provide former Acieux shareholders with the Nicox shares due to them in respect of their category A-1 Contingent Value Rights (see the document dated 30 September 2014 registered with the *Autorité des Marchés Financiers* under no. E. 14-060 available on Nicox' website). These new shares are issued at their nominal value and fully paid up, with the amount deducted from the acquisition premium account.

The impact of the issue on the stake held in the Company's share capital and the share of equity as at 31 December 2016 of a shareholder holding 1% of share capital at the time of the issue (calculations based on a non-diluted basis and a fully diluted basis, i.e. taking into account the issuance of a maximum of 1,578,822 new shares following (i) the exercise of all the Contingent Value Rights and stock options, (ii) the definitive acquisition of all free shares outstanding and), (iii) the issue of new shares to result from Categories B and C Contingent Value Rights granted to the former shareholders of Acieux is as follows:

	Total number of Nicox shares outstanding	Shareholder's interest	Share of equity
Before issue of 597,897 new shares	25 071 441	1.00%	€1 045 490,0
After issue of 597,897 new shares (non-diluted basis)	25 669 338	0.98 %	€1 080 628,4
After issue of 597,897 new shares and of 1,578,822 new shares resulting from outstanding share rights (fully diluted basis)	27 248 160	0.92 %	€1 102 069,2

About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has an approved NDA product and another product at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Hugo Solvet	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France
Stifel	Christian Glennie	London, UK



Upcoming financial and business conferences

June 19-22	2017 BIO International Convention	San Diego, US
September 25-27	Cantor Fitzgerald's 3rd Annual Healthcare Conference	New York; US

Contacts

Nicox

Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investor Relations

Europe

NewCap
Julien Perez, Valentine Brouchet
T +33 (0)1 44 71 94 94
nicox@newcap.eu

United States

Argot Partners
Melissa Forst
T +1 (212) 600-1902
melissa@argotpartners.com

Media Relations

United Kingdom

Jonathan Birt
T +44 7860 361 746
jonathan.birt@ymail.com

France

NewCap
Nicolas Merigeau
T +33 (0)1 44 71 94 98
nicox@newcap.eu

United States

Argot Partners
Eliza Schleichstein
T +1 (917) 763-8106
eliza@argotpartners.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.



Nicox S.A.

Drakkar 2

Bât D, 2405 route des Dolines

CS 10313, Sophia Antipolis

06560 Valbonne, France

T +33 (0)4 97 24 53 00

F +33 (0)4 97 24 53 99